Articular manifestations in primary Sjögren's syndrome: Clinical significance and prognosis of 188 patients

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1164-1172

  Fauchais, Anne Laure ^a,b   Ouattara, Bali ^a   Gondran, Guillaume ^a   Lalloué, Fabrice ^b   Petit, Daniel ^b   Ly, Kim ^a   Lambert, Marc ^a   Launay, David ^a   Loustaud Ratti, Véronique ^a   Bezanahari, Holly ^a   Liozon, Eric ^a   Hachulla, Eric ^a   Jauberteau, Marie Odile ^b   Vidal, Elisabeth ^a   Hatron, Pierre Yves ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Articular manifestation; Hydroxychloroquine; Primary Sj gren's syndrome

Indexed keywords

ALLOCHRYSINE; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; ARTHROPATHY; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; FRANCE; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; SJOEGREN SYNDROME; SYMPTOM; SYNOVITIS; VASCULITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; COHORT STUDIES; FEMALE; FRANCE; HUMANS; HYDROXYCHLOROQUINE; JOINT DISEASES; JOINTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SJOGREN'S SYNDROME;

EID: 77953507906     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq047     Document Type: Article

References (49)

1. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000;12:391-8.
2. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren's syndrome: a clinical, pathological and serological study of sixty-two cases. Medicine 1965;44:187-231.
3. Castro-Poltronieri A, Alarcon-Segovia D. Articular manifestations of primary Sjögren's syndrome. J Rheumatol 1983;10:485-8.
4. Molina R, Provost TT, Arnett FC et al. Primary Sjögren's syndrome in men: clinical, serologic and immunogenetic features. Am J Med 1986;80:23-31.
5. Brennan MT, Fox PC. Sex differences in primary Sjögren's syndrome. J Rheumatol 1999;26:2373-6.
6. Diaz-Lopez C, Geli C, Corominas H et al. Are there clinical or serological differences between male and female patients with primary Sjögren's syndrome? J Rheumatol 2004;31:1352-5.
7. Gondran G, Fauchais A, Lambert M et al. Primary Sjögren's syndrome in men. Scand J Rheumatol 2008;37:300-5.
8. Cervera R, Font J, Ramos-Casals M et al. Primary Sjögren's syndrome in men: clinical and immunological characteristics. Lupus 2000;9:61-4.
9. Pavlidis NA, Karsh J, Moutsopoulos HM. The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol 1982;9:685-90.
10. Pease CT, Shattles W, Barrett NK, Maini RN. The arthropathy of Sjögren's syndrome. Br J Rheumatol 1993;32: 609-13.
11. Fauchais A, Lambert M, Dubucquoi S et al. Inaugural Raynaud's phenomenon is associated with a multisystemic involvement during follow-up in primary Sjögren's syndrome a report of 162 patients. Int J Angiol 2004;13: 1061-711.
12. Ramos-Casals M, Anaya JM, Garcia-Carrasco M et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine 2004;83:96-106.
13. Garcia-Carrasco M, Ramos-Casals M, Rosas J et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002; 81:270-80.
14. Ramos-Casals M, Cervera R, Yague J et al. Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998;28:200-5.
15. Gottenberg JE, Mignot S, Nicaise-Rolland P et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64:114-7.
16. Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren's syndrome in the north east of England: a long-term follow-up study. Rheumatology 1999;38:245-53.
17. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological and epidemiological aspects. Ann Rheum Dis 2001;60:467-72.
18. Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64: 1062-4.
19. Dubucquoi S, Solau-Gervais E, Lefranc D et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004;63: 415-9.
20. Bousquet E, Ecoiffier M, Tubery M et al. Systemic manifestations of primary Sjögren syndrome. Presse Med 1997;26:995-1010.
21. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med 1988;85:62-7.
22. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996;5(Suppl. 1): S31-6.
23. Kruize AA, Hene RJ, Kallenberg CG et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two-year double blind crossover trial. Ann Rheum Dis 1993;52:360-4.
24. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002;61:554-8.
25. Van Bijsterveld O. Diagnosis and differential diagnosis of keratoconjunctivitis sicca associated with tear gland degeneration. Clin Exp Rheumatol 1990;8:3-6.
26. Schall G, Andferson L, Wolf R et al. Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy. JAMA 1971;216:2109-16.
27. Chisholm D. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968;21:656-60.
28. Boutry N, Hachulla E, Flipo RM, Cortet B, Cotten A. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome. Radiology 2005;236: 593-600.
29. Hill MO, Gauch HG. Detrended correspondence analysis: an improved ordination technique. Vegetatio 1980;42: 47-58.
30. Hammer O, Harper DAT, Ryan PD. Past: paleontological statistics software package for education and data analysis. Palaeontol Electronica 2001;4:9-22.
31. Ramos-Casals M, Solans R, Rosas J et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 2008;87: 210-9.
32. Pease CT, Shattles W, Charles PJ, Venables PJ, Maini RN. Clinical, serological and HLA phenotype subsets in Sjögren's syndrome. Clin Exp Rheumatol 1989;7: 185-90.
33. Brennan MT, Pillemer SR, Goldbach-Mansky R, El-Gabalawy H, Schumacher HR Jr, Fox PC. Focal sialadenitis in patients with early synovitis. Clin Exp Rheumatol 2001;19:444-6.
34. Solau-Gervais E, Legrand JL, Cortet B, Duquesnoy B, Flipo RM. Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study. J Rheumatol 2006;33:1760-5.
35. Ramos-Casals M, Cervera R, Font J et al. Young onset of primary Sjögren's syndrome: clinical and immunological characteristics. Lupus 1998;7:202-6.
36. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29: 296-304.
37. Treves R, Vergne P, Bonnet C, Bertin P. Concomitant ankylosing spondylitis and Sjögren's syndrome in three patients. Rev Rhum Engl Ed 1998;65:801.
38. Kobak S, Kobak AC, Kabasakal Y, Doganavsargil E. Sjögren's syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007;26:173-5.
39. Atzeni F, Sarzi-Puttini P, Lama N et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008;10:R51.
40. Bjerrum K, Prause JU. Primary Sjögren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 1990;8:283-8.
41. Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002;323:190-3.
42. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996;14:555-8.
43. Royer B, Cazals-Hatem D, Sibilia J et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90: 766-75.
44. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren's syndrome: one-year followup. Arthritis Rheum 2002;46:3301-3.
45. Mariette X, Ravaud P, Steinfeld S et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004;50: 1270-6.
46. Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
47. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004;31:96-101.
48. Seror R, Sordet C, Guillevin L et al. Tolerance and effi-cacy of rituximab and changes in serum B-cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007;66:351-7.
49. Steinfeld SD, Demols P, Van Vooren JP, Cogan E, Appelboom T. Zidovudine in primary Sjögren's syndrome. Rheumatology 1999;38:814-7.